Progyny sees 2022 EPS 28c-29c, consensus 27c

Sees 2022 revenue $781.5M-$786.5M, consensus $780.53M. Progyny announced that it is raising its financial guidance for the fourth quarter and full year period ending December 31, 2022, in light of the resumption in the deliveries of Menopur, a commonly prescribed fertility medication, following the previously disclosed industry-wide shortage in the supply of that medication. During its earnings call on November 3, 2022, the Company disclosed that the shortage of this medication was expected to impact its fourth quarter results, given the different unit economics associated with the medications that would be used as alternatives by Progyny members while continuing to pursue their treatments. As disclosed on the call, the Company’s financial guidance for the fourth quarter at that time had assumed that Menopur would not be available for the remainder of 2022. Given the need to dispense medication in advance of scheduled fertility treatment cycles, the significant majority of the dispensing for the cycles that were expected to be impacted by the shortage has already occurred. Accordingly, the Company is increasing its guidance to reflect the positive impact now expected in the fourth quarter. The Company expects that historical prescribing and dispensing patterns will resume by the end of 2022.